Outokumpu


Q326 : decent. Outlook : much worse.

10/11/26 -"We have substantially cut our forecasts after the release of the Q326 numbers. They showed a rather muted picture, but worse, the outlook given for Q4 was particularly weak, with an expected fall in ..."

Pages
73
Language
English
Published on
10/11/26
You may also be interested by these reports :
10/11/26
In the light of higher earnings, our target price resets some 14% higher. It also benefits from a higher premium to peers (20% vs 10% previously), ...

10/11/26
We have substantially cut our forecasts after the release of the Q326 numbers. They showed a rather muted picture, but worse, the outlook given for ...

06/11/26
Aperam’s Q326 results are slightly below consensus but broadly in line with previous guidance, with EBITDA reaching €103m. Despite weak European ...

06/11/26
Outokumpu’s Q326 results were broadly in line with expectations, with sales up 19.8% to €1,555m and adjusted EBITDA of €101m. However, the outlook is ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO